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ABSTRACT 
Objective: The objective of this research was to improve the dissolution rate of gliclazide by solid dispersion technique with poloxamer 188, HPMC, 
and Eudragit®
Methods: Solid dispersions were prepared by solvent evaporation methods in the binary and ternary system. In binary system gliclazide was mixed 
with poloxamer188 in the ratio of 1:0.5, 1:0.75, 1:1, 1:1.5 and 1:2, with HPMC in the ratio of 1:0.1, 1:0.125, and 1:0.25, and with Eudragit
 E100 as carriers.  
® E100 in 
1:0.25 ratio. In ternary system gliclazide was prepared with poloxamer188 and HPMC in the ratio of 1:2:0.1 and 1:2:0.25, and with poloxamer188 
and Eudragit®
Results: At the 15
 E100 in the ratio of 1:1:0.25 and 1:2:0.25. Pure gliclazide, solid dispersions, and physical mixtures were characterized by dissolution 
testing, DSC, FTIR, dan XRD.  
th minute, the highest dissolution rate observed from binary and ternary solid dispersions of gliclazide were from gliclazide-
poloxamer188 1:2 dan gliclazide-poloxamer188 and Eudragit®
Conclusion: The results of this study 
 E100 1:2:0,25 which showed 12 and 15 fold increase in dissolution rate compared 
by pure gliclazide. The decrease of endothermic peak (DSC) and the intensity of the diffraction pattern by XRD of solid dispersions showed the 
decrease of crystallinity rate. Characterization by FTIR virtually showed no shift of absorption peaks of gliclazide on solid dispersion. 
indicate that the solid dispersion of gliclazide using poloxamer and Eudragit®
Keywords: Dissolution, Gliclazide, Solid dispersions, Poloxamer 188, HPMC, Eudragit
E100 in 1:2:0, 25 ratio of weight 
was the best in enhancing the dissolutions characteristics and bioavailability. 
®




Drugs with low solubility which belongs to a class II and IV BCS 
(Biopharmaceutics Classification System) will have less bioavailability 
because the drug particles dissolve slowly. One technique that can 
improve the drugs dissolution which can improve its bioavailability is 
through solid dispersion [1]. Solid dispersion is a dispersion of one or 
more active ingredients in an inert carrier or matrix prepared by the 
melting, solvent, or melting-solvent method. Solid products consisting 
of generally a hydrophilic matrix and a hydrophobic drug. The matrix 
can be either crystalline or amorphous. The drug can be dispersed 
molecularly [2]. Gliclazide (GLK) is a second-generation sulfonylurea 
of an antihyperglycemic oral, widely used for the treatment of type II 
diabetes mellitus (NIDDM or Non-Insulin Dependent Diabetes 
Mellitus) [3]. Gliclazide includes in the class II biopharmaceutics, 
which has a high permeability and low solubility [4]. Solid dispersion 
used on gliclazide is intended to increase its dissolution rate. 
Poloxamers are nonionic copolymers composed of a central  
hydrophobic chain of polypropylene flanked by two hydrophilic chains 
of polyoxyethylene. Most poloxamers function are as surfactants, 
emulsifying agents, cleansing and/or solubilizing agents. 
Hydroxypropyl methylcellulose (HPMC) is a hydrophilic polymer that 
is soluble in water, which is stable and hygroscopic. HPMC used as 
stabilizers, suspending agents, tablet binders and viscosity enhancer 
[5]. Eudragit® E100 is a cationic polymer consisting of dimethylamino 
ethyl methacrylate, butyl methacrylate, and methyl methacrylate in 
the ratio 2: 1: 1. Eudragit® E100 has a low viscosity and its solubility is 
influenced by physiological conditions of the gastrointestinal tract. 
Eudragit® E100 dissolve at a pH of up to 5 and will develop and 
permeable at a pH above 5 [5, 6]. Less investigation on a ternary 
system of gliclazide solid dispersion has been found. Therefore, the 
present study was meant to obtain a dissolution formulation of 
gliclazide with a better method solid dispersions with poloxamer 188, 
HPMC, Eudragit® E100, as the combination of carrier poloxamer 188-
HPMC, and poloxamer 188-Eudragit® E100. 
MATERIALS AND METHODS  
Materials 
Gliclazide (PT. Kalbe Farma Tbk), poloxamer 188 (BASF), 
HPMC/Methocel E6 LV (PT. Kalbe Farma Tbk), Eudragit® E100 (PT. 
Sanbe Farma), hydrochloric acid (HCl) 37% pro analysis (Merck), 
methanol, dichloromethane, distilled water and other reagents 
associated with the research. 
Preparation of the solid dispersion by solvent evaporation 
The solid dispersion was made by mixing the active ingredient and 
the carrier according to the comparison in table 1. Gliclazide was 
dissolved in methanol, poloxamer 188 was dissolved in distilled 
water, HPMC was dissolved in a mixture of water: methanol (1: 1), 
Eudragit® E100 was dissolved in dichloromethane. Then gliclazide 
and the carrier solution were mixed until homogeneous using a 
magnetic stirrer. Solid dispersion solution mixture was then 
evaporated on a water bath at a temperature of 50-60 °C, then dried 
in an oven 50 °C for 1-2 h. Dry mass was stored in desiccators. 
Furthermore, the mass of dry solid dispersion crushed and sieved to 
gain a size<125 μm particle [7]. 
Preparation of physical mixture 
The physical mixture was made by mixing gliclazide and the carrier 
in a mortar without crushing. Eudragit® E100 first crushed and 
sieved to gain a size<354μm 
The dissolution test carried out in acidic media 0,1N HCl pH 1.2 900 
ml using a type II dissolution apparatus with a rotation speed of 100 
rpm and a temperature of 37±0.5 °C. The sample used is equivalent 
to 80 mg gliclazide. The sampling is done in minutes: 5, 10, 15, 30, 
45, 60, 90, 120, 150, 180, 210 and 240. The diluted test solution was 
then measured absorbance at a wavelength of 228 nm. 
particle. 
In vitro dissolution study 
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Table 1: Composition of solid dispersion and physical mixture gliclazide 
Formulation Carrier Ratio drug: carrier Methods 
SD PLX 1 Poloxamer 188 1: 0.5 Solvent evaporation 
SD PLX 2 1: 0.75 
SD PLX 3 1: 1 
SD PLX 4 1: 1.5 
SD PLX 5 1: 2 
PM PLX 1: 2 Physical 
SD HPMC 1 
Mixture 
HPMC 1: 0.1 Solvent evaporation 
SD HPMC 2 1: 0.125 
SD HPMC 3 1: 0.25 
PM HPMC 1: 0.25 Physical 
SD EUD 1 
Mixture 
Eudragit® 1: 0.25 E100 Solvent evaporation 
PM EUD 1: 0.25 Physical 
SD PLX-HPMC 1 
Mixture 
Poloxamer 188–HPMC 1: 2: 0.1 Solvent evaporation 
SD PLX-HPMC 2 1: 2: 0.25 
PM PLX-HPMC 1: 2: 0.25 Physical 
SD PLX-EUD 1 
Mixture 
Poloxamer 188-Eudragit® 1: 1: 0.25 E100 Solvent evaporation  
SD PLX-EUD 2 1: 2: 0.25 
PM PLX-EUD 1: 2: 0.25 Physical Mixture 
SD: Solid Dispersion, PM: Physical Mixture 
 
Characterization of solid dispersions 
Solid dispersions were characterized by differential scanning 
calorimetry (DSC), the FTIR spectra, and X-Ray Diffraction of pure 
drug and their solid dispersions. DSC curves of Solid Dispersions and 
Physical Mixture were obtained by Differential Scanning Calorimetry 
(Perkin Elmer). The FTIR spectra of pure drug and their solid 
dispersions were obtained on a Perkin–Elmer type one by using KBr 
disc method. The scanning range was 400 to 4000 cm-1
Data analysis 
 and the 
resolution was 4 cm-1. X-Ray Diffraction testing was obtained by 
Shimadzu X-Ray Diffractometer. Testing with X-Ray diffraction was 
conducted at room temperature, with Cu as an anode and a 
monochromatic graphite. Tests performed on 40kV voltage, current 
25 mA. The samples were analyzed at an angle 2θ in the range 5-700 
and process parameters set at 0.020 scans stage (2θ) and sweep 
speed coupe/0.5 seconds. 
The similarities between the results of dissolution testing of solid 
dispersion and physical mixture with pure gliclazide were carried 
out using the formula as follows:  
 
With: n = number of sampling points 
Rt = percent on average solute at time t for formula 1 
Tt = percent on average solute at time t for formula 2 
RESULTS AND DISCUSSION 
The dissolution test gliclazide from solid dispersions showed that 50% 
gliclazide had been released after the 10th minute on all-
poloxamer188 comparison gliclazide, for gliclazide-HPMC after the 
60th minute, and the gliclazide-Eudragit® E100 after the 15th minute. 
The dissolution test solid dispersions of gliclazide-poloxamer 188 
shows that the greatest dissolution rate obtained from solid 
dispersion gliclazide-poloxamer 188 in the ratio of 1: 2 (BD1) which 
is reached at minute 120. In the solid dispersions of gliclazide-HPMC 
greatest dissolution rate indicated by gliclazide-HPMC at a ratio of 1: 
0.25 (BD2). Gliclazide-solid dispersion Eudragit® E100 is made only 
at a ratio of 1: 0:25 (BD3) [8]. This study focused on the use of 
Eudragit® E100 in the ternary system wherein solid dispersion is 
made with a combination of the two carriers. 
The dissolution test solid dispersion with a combination of two 
carriers results dissolution rate of solid dispersions of gliclazide-
poloxamer188-HPMC (TD1) and gliclazide-poloxamer188-
Eudragit®E100 greater in the ratio 1: 2: 0.25 (TD2). 
 
Fig. 1: Dissolution profile of pure drug and solid dispersion 
system of binary and ternary 
*note: error bars have been omitted for simple presentation 
 
Statistical analysis ƒ2 between BD1 and BD3 with 2 BD, TD 1 and 
TD2, against BD3 BD2, BD3 TD1, and TD2 and against TD1 and TD2 
ƒ2 value<50, which means no Similar dissolution rate. Similar results 
of the dissolution rate (ƒ2>50) were obtained from BD1 comparison 
with TD1, TD2, and BD1 with TD1 to TD2. 
Comparison between physical mixture of binary and ternary 
systems gliclazide-poloxamer188 1: 2 (BC1), gliclazide-HPMC 1: 0.25 
(BC2), gliclazide-Eudragit®E100 1: 0.25 (BC3), gliclazide-poloxamer 
188-HPMC 1: 2: 0.25 (TC1) and gliclazide-poloxamer 188-
Eudragit®E100 1: 2: 0.2 (TC2) gives the following results:  
 
 
Fig. 2: Dissolution profile of pure drug and physical mixture of 
binary and ternary systems 
*note: error bars have been omitted for simple presentation 
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Statistical analysis ƒ2 for pure gliclazide with BC1, BC2, BC3, TC1 and 
TC2, BC1 to BC2, BC3, TC1 and TC2, TC1 and TC2 BC3 with the 
obtained results<50. These results give meaning between the 
dissolution rate of a physical mixture of the above is no Similar, 
Similar dissolution rate were obtained between a physical mixture of 
BC2 to BC3 danTC1 comparison with the value TC2 54.55 and 70.65. 
For statistical analysis ƒ2 BC2 with TC1 and TC2 cannot be done 
because RSD for BC2 on the first point>20% while for the point of 
the 2nd, 3rd and 4th of>10%. 
The dissolution rate of solid dispersions between BD1 with TD 1 and 
TD2 was similar, the addition of this shows the carrier (HPMC and 
llEudragit® E100) does not provide a different dissolution rate. 
Solid dispersion either in binary or in the ternary system by using 
carrier poloxamer 188 showed increased dissolution rate is quite 
high. In the 15th minute a solid dispersion gliclazide-poloxamer 188 
1: 2 gives the dissolution rate 12 times greater than pure gliclazide, 
gliclazide-HPMC 1: 0.25 dissolution rate increased 5 times, 
gliclazide-Eudragit®E100 1: 0.25 increases 10 times, gliclazide-
poloxamer188-HPMC 1: 2: 0.25 14 times and gliclazide-
poloxamer188-Eudragit®E100 1: 2: 0.25 15 times greater than pure 
gliclazide. Solid dispersion gliclazide-poloxamer188 1: 2, gliclazide-
poloxamer188-HPMC 1: 2: 0.25 and gliclazide-poloxamer-Eudragit® 
E100 1: 2: 0.25 in the 90th minute almost 100% gliclazide has been 
dissolved. 
Increase mechanism in dissolution rate in the presence of 
amphiphilic surfactants such as poloxamer 188 through a 
reduction in surface tension between the drug with solvents, 
wetting and solubilization micelles increase of drug [9]. Another 
possibility is the formation of intermolecular interactions 
between the polymer gliclazide. Interactions that occur due to 
the formation of hydrogen bonds between the H atoms from the 
group NH gliclazide with O atoms of poloxamer 188. But 
solubilization mislead in this study did not happen because of 
solubilization micellar can only occur if the surfactant 
concentration above the critical micelle concentration (CMC). 
CMC to poloxamer 188 is 1.25 x 10-4 M [10]. 
HPMC carrier increases the dissolution rate of the solid dispersion as 
HPMC would slow down the process of re-crystallization of 
gliclazide. Medicinal compounds will lose its crystalline form in an 
HPMC matrix so that the dissolution rate becomes larger in the form 
of solid dispersions [11].  
Dissolution rate improvement with Eudragit® E100 as the carrier 
was possibly made as the interaction between a tertiary amine 
group of Eudragit® E100 with gliclazide through molecular 
interactions and dipolar interactions. Molecular interactions also 
occurred due to weak acidic gliclazide while Eudragit® E100 is a 
weak base [11]. 
A physical mixture of binary and ternary systems also provide 
increased dissolution rate compared to pure gliclazide can occur 
because when the physical mixture was added to the dissolution 
medium carrier will dissolve over time so will alter the 
hydrophilicity/lipophilicity or wetting of active substances that 
will enhance the dissolution. Another mechanism was a weak 
complex formation of the carrier with the active substance on 
the surface of the particles so that it will produce greater 
dissolution rate [12]. 
Pure Gliclazide characterization, solid dispersion, and physical 
mixture gliclazide-carrier by Differential Scanning Calorimetric 
(DSC) provide data calorimetric as shown below:  
In the solid dispersion and physical mixture decreased the melting 
point of gliclazide, followed by a decrease in enthalpy which 
indicates the amount of energy required for a lower dissolution due 
to a decrease in the crystalline degree. 
The spectra FTIR of pure drug, solid dispersions and physical 
mixture has been shown in fig. 6, 7, 8 and 9. 
 
Fig. 3: DSC thermogram BD1, BD2, and BD3 
 
 
Fig. 4: DSC thermogram BC1, BC2, and BC3 
 
 
Fig. 5: DSC thermogram TD1, TD2, TC1, and TC2 
 
In the solid dispersion and physical mixture, peak characteristic 
for gliclazide still apparent at specific hardly shifted wavelength. 
The interaction between the active substance and the carrier can 
be determined if there was a change in the functional groups 
spectrum C = O, S = O, and NH. Hydrogen chain can occur on the 
hydroxyl on poloxamer 188 group with the carbonyl on 
gliclazide group and the interaction between the hydrogen atoms 
of the NH gliclazide group with an oxygen atom of poloxamer 
188 (Patil and Galkwad, 2009). In the FTIR spectra of all samples 
(BD1, BD2, BD3, BC1, BC2, BC3, TD1, TD2, TC1, and TC2) did not 
indicate a shift so revealed no interaction between the carrier 
gliclazide [12]. 
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Fig. 6: FTIR spectra of pure drug (a), BD3, BD2, and BD1 (from bottom to top) 
 







Fig. 7: FTIR spectra BC1, BC2, and BC3 (from top to bottom) 
 




















Fig. 8: FTIR spectra of pure drug (a), TD1, and TD 2 (from top to bottom) 
 




















Fig. 9: FTIR spectra of pure drug (a), TC1, and TC2 (from top to bottom) 
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Fig. 10: X-ray diffraction pattern of gliclazide, Eudragit®E100, 
HPMC, and poloxamer 188 (from bottom to top) 
 
X-ray diffraction spectra of pure gliclazide gave high-intensity peaks at 
2θ 10.56, 17.94, 18.20, and 20.84. X-ray diffraction pattern on 
poloxamer 188 carrier, two peaks apparent at 2θ with high intensity at 
19.24 and 23.36 shows the crystalline the character of the poloxamer 
188. The peak was not appeared at HPMC and Eudragit®E100, which 
means the second form of this carrier, is amorphous. 
 
 
Fig. 11: X-ray diffraction pattern of gliclazide Pure, BD1, BD2, 
and BD3 (from bottom to top) 
 
 
Fig. 12: X-ray diffraction pattern of pure gliclazide, BC1, BC2, 
and BC3 (from bottom to top) 
 
 
Fig. 13: X-ray diffraction patterns of pure gliclazide, TD1, TD2, 
TC1, and TC2 (from bottom to top) 
In general, the decrease in intensity of the diffraction pattern for 
solid dispersion gliclazide and physical mixture compared with pure 
gliclazide showed a decline in the crystalline gliclazide degree. This 
might improve the dissolution rate [13]. 
The decrease in intensity occurred in the solid dispersion systems 
with poloxamer 188, because the concentrations of poloxamer 188 
are large enough to make a diffraction pattern dominant. At the 
same time as the carrier of Eudragit®E100 HPMC is relatively 
small due to low carrier concentration and does not change the 
character of the drug crystalline when compared to poloxamer 
188. The peak of poloxamer 188 in solid dispersion same with the 
diffraction pattern of pure poloxamer 188, it indicates the absence 
of chemical interactions between gliclazide with poloxamer 188 
[12]. 
CONCLUSION 
Gliclazide solid dispersion with poloxamer 188 1: 2 compared with 
solid dispersions of gliclazide-poloxamer188-HPMC 1: 2: 0.25 and 
gliclazide-poloxamer 188-Eudragit® E100 1: 2: 0.25 provide the 
similar dissolution rate 
In the 15th minute the dissolution rate of solid dispersions of 
gliclazide-poloxamer 188 1:2, gliclazide-HPMC 1:0.25, gliclazide-
Eudragit® E100 1:0.25, gliclazide-poloxamer188-HPMC 1:2:0.25 
and gliclazide-poloxamer 188-Eudragit® E100 1:2:0.25 
respectively giving the dissolution rate 12 times, 5 times, 10 times, 
14 times, and 15 times greater than the rate of dissolution of pure 
gliclazide. 
Characterization by DSC showed a decrease of gliclazide 
endothermic peak due to the decrease in gliclazide crystalline 
degree. FTIR spectra showed no absorption peak movement from 
functional groups of gliclazide. A decrease in intensity of the 
gliclazide diffraction pattern in solid dispersions showed a decrease 
in the degree of crystalline gliclazide. 
CONFLICT OF INTERESTS 
Declared none  
REFERENCES 
1. Saharan VA, Kukkar V, Kataria M, Gera M, Choudhory PK. 
Dissolution enhancement of drugs, part i: technologies and 
effect of carriers. Int J Health Res 2009:107-24. 
2. Chiou WL, Riegelman S. Pharmaceutical applications of solid 
dispersion systems. J Pharm Sci 1971;60:1281-302. 
3. Davis NS. Insulin, oral hypoglycemic agents and the 
pharmacology of the endocrine pancreas. In: Goodman and 
Gilman’s: The Pharmacological Basic of Therapeutics. 11th
4. Benet LZ. Predicting drug absorption and disposition using a 
biopharmaceutics drug disposition classification system and its use 
in deriving QSAR Approaches, Department of Biopharmaceutical 
Sciences University of California, San Francisco; 2007. 
 ed. 
LL Brunton, JS Lazo, KL Parker. Eds. Mc Graw-Hill Inc., New 
York; 2006. p. 1634–7. 
5. Rowe RC, Sheskey PJ, Quinn ME. Handbook of pharmaceutical 
excipients, 6th
6. Evonik Industries. Solubility Enhancement. In: Eudragit
 ed., Pharmaceutical Press: London; 2009. p. 506-
8, 517-21, 525-33.  
® 
Application Guidelines. 11th
7. Jalali MB, Maleki N, Garjani A, Khandar AA. Enhancement of 
dissolution rate and anti-inflammatory effects of piroxicam using 
solvent deposition technique. Drug Dev Ind Pharm 2002;28:681-6.  
 ed. Evonik Rohm GmbH, 
Darmstadt; 2009. p. 1-10. 
8. Amitya R. Peningkatan Laju Disolusi Gliklazid pada 
Pembentukan Dispersi Padat dalam Polimer Eudragit®
9. Savic R, Eisenberg A, Maysinger D. Block copolymer micelles as 
delivery vehicles of hydrophobic drugs: micelle-cell 
interactions. J Drug Target 2006;14:343-55.  
 E100, 
Skripsi, Sekolah Farmasi, Institut Teknologi Bandung; 2011. 
10. Maskarinec SA, Hannig J, Lee RC, Lee KYC. Direct observation of 
poloxamer 188 insertions into lipid Monolayers. Biophys J 
2002;82:1453-9.  
Wardiyah et al.  
Int J Pharm Pharm Sci, Vol 8, Issue 8, 363-368 
 
368 
11. Suzuki H, Miyamoto N, Masada T, Hayakawa E, Ito K. Solid 
dispersions of benidipine hydrochloride. I. preparations using 
different solvent systems and dissolution properties. Chem 
Pharm Bull 1996;44:364-71.  
12. Patil MP, Galkwad NJ. Preparation and characterization of 
gliclazide-polyethylene glycol 4000 solid dispersions. Acta 
Pharm 2009;59:57-65. 
13. Shavi GP. Enhanced dissolution and bioavailability of gliclazide 
using solid dispersion techniques. Int J Drug Delivery 
2010;2:49-57. 
How to cite this article 
• Wardiyah, Sukmadjaja Asyarie, Saleh Wikarsa. Preparation and 
characterization of gliclazide solid dispersion in binary and 
ternary system. Int J Pharm Pharm Sci 2016;8(8):363-368. 
 
